ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2018
Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 131 citations in OpenAlex.
- Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial.PLoS medicine · 2021Trial
- A multicenter kidney transplantation study identifies hierarchy and directionality of HLA-DQ alloimmune responses.Nature communications · 2026Article
- Influence of intrapatient variability in tacrolimus trough levels on acute rejection in pediatric kidney transplant recipients.Pediatric nephrology (Berlin, Germany) · 2026Article
- Clinical Outcomes and Quality of Life in Older De Novo Kidney Transplant Recipients Under Once-Daily Tacrolimus Formulations: The BITACORA Study.Clinical transplantation · 2026Article
- Bisphosphonates as a Tacrolimus-Sparing Strategy in Kidney Transplantation: Insights from a Retrospective Analysis.Yonsei medical journal · 2026Article
- Elevated tacrolimus exposure variability predicts transplant renal insufficiency.Frontiers in immunology · 2026Article
- The predictive value of tacrolimus intrapatient variability and time in therapeutic range for renal transplant outcomes.Renal failure · 2025Article
- Tacrolimus-Sirolimus Combined Exposure and Acute Rejection in Kidney Transplant Recipients Undergoing Early Conversion to Sirolimus: A Multicenter Retrospective Cohort Threshold Analysis.Journal of clinical medicine · 2025Article
- Impact of Tacrolimus Trough Levels at Discharge on Early Post-Kidney Transplantation Outcomes: A Nationwide Cohort Study.Journal of clinical medicine · 2025Article
- Maintenance Immunosuppression in Kidney Transplantation: A Review of the Current Status and Future Directions.Journal of clinical medicine · 2025Review
- Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Update on Maintenance Immunosuppression in Intestinal Transplantation.Gastroenterology clinics of North America · 2024Review
- Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data.The pharmacogenomics journal · 2024Article
- Exploratory associations of tacrolimus exposure and clinical outcomes after lung transplantation: A retrospective, single center experience.European journal of clinical pharmacology · 2024Observational
- Tacrolimus's Time Below Therapeutic Range Is Associated With Acute Pancreatic Graft Rejection and the Development ofTransplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Association of high intra-patient variability in tacrolimus exposure with calcineurin inhibitor nephrotoxicity in kidney transplantation.Scientific reports · 2023Article
- Rejection markers in kidney transplantation: do new technologies help children?Pediatric nephrology (Berlin, Germany) · 2023Review
- Contemporary Biomarkers for Renal Transplantation: A Narrative Overview.Journal of personalized medicine · 2023Review
- Higher tacrolimus trough levels and time in the therapeutic range are associated with the risk of acute rejection in the first month after renal transplantation.BMC nephrology · 2023Article
- Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers.Clinical transplantation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
De novo donor-specific antibodies (dnDSAs) have been associated with reduced graft survival. Tacrolimus (TAC)-based regimens are the most common among immunosuppressive approaches used in in clinical practice today, yet an optimal therapeutic dose to prevent dnDSAs has not been established. We evaluated mean TAC C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.